Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer (THOR)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.
Sponsor:
Collaborator:
OnkoDataMed GmbH
Information provided by (Responsible Party):
Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.
ClinicalTrials.gov Identifier:
NCT01985893
First received: November 10, 2013
Last updated: August 29, 2014
Last verified: August 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2019
  Estimated Primary Completion Date: September 2018 (Final data collection date for primary outcome measure)